Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 784
Aptamer sequence: CGTACGGAATTCGCTAGCGGGCGGGGGTGCTGGGGGAATGGAGTGCTGCGTGCTGCGGGGATCCGAGCTCCACGTG
Target unique ID: 54704426
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_708 T24 Molecule Tetracycline hydrochloride 70.7 nM 100 mM NaCl, 20 mM Tris-HCl (pH 7.6), 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2, 0.02% Tween-20 18617415
Structure information of aptamer
Aptamer Sequence: CGTACGGAATTCGCTAGCGGGCGGGGGTGCTGGGGGAATGGAGTGCTGCGTGCTGCGGGGATCCGAGCTCCACGTG
The optimal secondary structure in dot-bracket notation: .((.((((.(((((.((((.((...((((((..........)))))))).)))))))))..)))).))........
The centroid secondary structure in dot-bracket notation: ............................................................................
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_708 Description T24
Aptamer chemistry DNA Length 76 nt
GC content 68.4% Molecular weight 23,767.11 Da
Molarity of 1 μg/μl solution 42.07 μM Number of G-quadruplexes 3
G-Score 52 Function Target detection
Sequence CGTACGGAATTCGCTAGCGGGCGGGGGTGCTGGGGGAATGGAGTGCTGCGTGCTGCGGGGATCCGAGCTCCACGTG
Applications Detection of TCs in pharmaceutical preparations and contaminated food products
Target information
Type Detail Type Detail
PubChem ID 54704426 Molecular name Tetracycline hydrochloride
Molecular formula C22H25ClN2O8 Molecular weight 480.9
IUPAC name (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride InChIKey YCIHPQHVWDULOY-FMZCEJRJSA-N
LogP 0.051 Topological polar surface area 181.62
Hydrogen bond acceptor 9 Hydrogen bond donor 6

Synonym(s):
TETRACYCLINE HYDROCHLORIDE; 64-75-5; Tetracycline HCl; Achromycin hydrochloride; Tetracycline (hydrochloride); Supramycin; Sustamycin; Sumycin; Telotrex; UNII-P6R62377KV; NCI-C55561; MFCD00078142; Achromycin; Quatrex; P6R62377KV; Bristacycline; Dumocyclin; (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride; 64-75-5 (HCl); DSSTox_CID_1321; DSSTox_RID_76081; DSSTox_GSID_21321; Hostacycline; Mephacyclin; Quadracycline; Remicyclin; Stilciclina; Tetrabakat; Tetracompren; Tetralution; Tetramavan; Topicycline; Triphacyclin; Actisite; Artomycin; Diacycine; Partrex; Piracaps; Ricycline; Subamycin; Tefilin; Tetrabid; Tetrablet; Tetracaps; Tetrakap; Tetramed; Tetrosol; Paltet; Qidtet; Retet; Teline; Unicin; Tetra-wedel; Neocyclin B; Ro-Cycline; Tetracycline.HCl; Polyotic ointment; TetraSURE; Tet-cy; Tetra-D; Vetquamycin-324; Cancycline-250; (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride; Cefracycline tablets; Tetracycline chloride; Panmycin hydrochloride; Sentry av ornacycline; T-250 Capsules; Tetracyn hydrochloride; Tetraciclina cloridrato; ALA TET; Polycycline hydrochloride; Chlorowodorku tetracykliny; Chlorhydrate de tetracycline; CCRIS 2351; SR-01000000212; SR-05000001723; (-)-Tetrahcycline hydrochloride; Tetraciclina cloridrato [Italian]; Chlorowodorku tetracykliny [Polish]; (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride; Prestwick_434; EINECS 200-593-8; Bristacycline (TN); Chlorhydrate de tetracycline [French]; Tetracycline hydrochloride [USP:JAN]; Tetracycline hydrochloride (internal use); AI3-50120; CAS-64-75-5; NCGC00016291-01; EC 200-593-8; U-5965; SCHEMBL34248; SPECTRUM1500566; CHEMBL454950; DTXSID6021321; NCI-c55561;Tetracycline HCl; Tetracycline hydrochloride, powder; HMS1568K22; HMS1921C19; Pharmakon1600-01500566; HY-B0474; Tox21_110355; Tox21_200516; CCG-39267; NSC757338; s2574; AKOS015951263; Tox21_110355_1; BCP9000227; KS-1431; MCULE-8111555447; NSC 757338; NSC-757338; Tetracycline hydrochloride (JP17/USP); NCGC00017323-08; NCGC00180907-01; NCGC00180907-02; NCGC00258070-01; (4S,4aS,5aS,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride; (4S,6S,12aS,4aS,5aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,1 1-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide, chloride; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4S,4aS,5aS,6S,12aS)-; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-; K044; BCP0726000161; SW196293-4; D02122; D92606; SR-01000000212-4; SR-05000001723-2; Q27286287; Tetracycline hydrochloride 100 microg/mL in Acetonitrile; Tetracycline hydrochloride, meets USP testing specifications; Tetracycline hydrochloride, VETRANAL(TM), analytical standard; Tetracycline hydrochloride, >=95% (European Pharmacopoeia HPLC assay); Tetracycline hydrochloride, British Pharmacopoeia (BP) Reference Standard; Tetracycline hydrochloride, European Pharmacopoeia (EP) Reference Standard; Tetracycline hydrochloride, powder, BioReagent, suitable for cell culture; Tetracycline hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Tetracycline hydrochloride, United States Pharmacopeia (USP) Reference Standard; (4S,4AS,5AS,6S,12AR)-4-(DIMETHYLAMINO)-1,6,10,11,12A-PENTAHYDROXY-6-METHYL-3,12-DIOXO-3,4,4A,5,5A,6,12,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE HYDROCHLORIDE; (4S,4AS,5aS,6S,12aS)-4-(Dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide hydrochloride; (4S,4aS,5aS,6S,12aS,Z)-2-(amino(hydroxy)methylene)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione hydrochloride; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4S-(4alpha,4aalpha,5aalpha,6beta,12alpha))-; 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride,(4S,4aS,5aS,6S,12aS)-

Activity data
Interaction ID 784
Target type Molecule
Target unique ID 54704426
Activity 70.7 nM
Binding Conditions/Buffer

100 mM NaCl, 20 mM Tris-HCl (pH 7.6), 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2, 0.02% Tween-20
Assay

Binding assays with ssDNA aptamers to tetracycline (TET). The saturation curves were obtained by plotting the concentration of bound TET as a function of ssDNA concentration, and the dissociation constants (Kd) were calculated by non-linear regression analysis (n = 3)
PubMed ID 18617415
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_1117 DNA CGTACGGAATTCGCTAGCGGACTGGAGTCTAGACCGGGTAGCTGTGGTGGATCCGAGCTCCACGTG 76.32%
Apta_1116 DNA CGTACGGAATTCGCTAGCCGGGGTGGGAACCAGTCTTGCGCGGGTGACGGATCCGAGCTCCACGTG 73.68%
Apta_1115 DNA CGTACGGAATTCGCTAGCGGTGACGGACGTGGGGTGCACGAAGGGAGGGGATCCGAGCTCCACGTG 72.37%
Apta_1291 DNA CGTACGGAATTCGCTAGCCCCCCGGCAGGCCACGGCTTGGGTTGGTCCCACTGCGCGTGGATCCGAGCTCCACGTG 71.05%
Apta_572 DNA CCGTAACCCTGCGGGGGGGGGAGAAGGCAATGGGGGACAACTCGCCGGTAGCCATCCATAT 57.89%
Apta_616 DNA GGTGCGGGTAGGGATGAGGGCGGGTCGGGTTGAGTGTGAGCTTAGGGGtGGCGGATCTAC 55.26%
Apta_1035 DNA ATGCGGATCCCGCGCGGGTCTGAGGAGTGCGCGGTGCCAGTGAGTGCGCGAAGCTTGCGC 55.26%
Apta_1229 DNA CACGGGCAGAGGGATAGGTTGTTGACGGGGCTGGTGGGTGGGTGCGCTCGCGCTATCGTGG 55.26%
Apta_775 DNA GAATTCAGTCGGACAGCGCGGTGTTGGTGGCGGGGGTGGTTGGGGGATTTGGCTGTCCTGAGTGATGGACGAATATCGTCTCCC 54.76%
Apta_151 DNA GCAATGGTACGGTACTTCCGCGGTCCGGGGTGGGTGGGTGGTGGGGGGTGCGGGGGGGCGGCCGCAAAAGTGCACGCTACTTTGCTAA 54.55%
Apta_584 DNA GTACCAGCTTATTCAATTACACGGACAGAGGGTAGCGGCTCTGCGCATTGAGTTGCTGCGGGCTGAAGCGCGGTACATGGGAGATAGTATGTTCATCAG 54.55%
Apta_490 DNA GGGAGACAAGAATAAACGCTCAAGGGCGTGGTGGGTGGGGTACTAATAATGTGCGTTTGTTCGACAGGAGGCTCACAACAGGC 54.22%
Apta_45 DNA CGGGTGGGAGTTGTGGGGGGGGGTGGGAGGGTTCTTTGTTTGATCTTTCTCGCTGCCTGGCCCTAGAGTG 53.95%
Apta_1034 DNA ATGCGGATCCCGCGCGCGACCGTGTCAGCGGGGACTAGCGGTGTAGCGCGAAGCTTGCGC 53.95%
Apta_1082 DNA GGCTGGTCCGCTGGGAACAAGGGCGGGAGGGAGGGTGTGGGTGCGACAAGCGGACCAGCC 53.95%
Apta_454 DNA AGCTCCAGAAGATAAATTACAGGTGAGGGCGGGCGGGTGGTTGTAATATGATCGAATGGTATATGTGTGTTTGCAACTAGGATACTATGACCCCG 53.68%
Apta_950 DNA CACCTAATACGACTCACTATAGCGGATCCGAAGGGGGCGCGAGGTGTAAGGGTGTGGGGTGGTGGGTGGGCCTGGCTCGAACAAGCTTGC 53.33%
Apta_951 DNA CACCTAATACGACTCACTATAGCGGATCCGAGGGGGTAGCGGGTGGGCCGGTGGATGCGGGGCGCCGGCGCCTGGCTCGAACAAGCTTGC 53.33%
Apta_878 DNA TCGCACATTCCGCTTCTACCGGGGGGGTCGAGCTGAGTGGATGCGAATCTGTGGGTGGGCTTCGCACACACGGACTTAC 53.16%
Apta_44 DNA TCTCGGACGCGTGTGGTCGGGTGGGAGTTGTGGGGGGGGGTGGGAGGGTTCTTTGTTTGATCTTTCTCGCTGCCTGGCCCTAGAGTG 52.87%

ABOUT

AptaDB is an online database we developed to integrate comprehensive information about aptamer.
The detail of this database is described here:

HELP CENTER

>Contact us
>LMMD Group
>School of Pharmacy

DEV TOOL
Page last updated at 2022-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 43962
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.